Compare GSK plc (GSK) vs Vistra Corp (VST) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Vistra Corp. (VST) trades at $151.22, down 4.55% in the last session, showing recent volatility amid mixed earnings results. The stock exhibits bullish technical signals with strong analyst support (90.9% buy ratings) and a consensus price target of $253, representing significant upside. Recent earnings showed a Q1 2026 beat but Q3-Q4 2025 misses, while fundamentals reveal strong profitability (ROE 74.92%) and improving margins projected for 2026.

The outlook remains positive with AI-driven power demand catalysts and long-term PPAs with major tech companies supporting growth. Key risks include power price volatility, high debt levels, and execution risks on growth projects. The current valuation at 26.79 P/E appears reasonable given projected earnings growth and strategic positioning in the energy transition.